RIVA-LATANOPROST SOLUTION

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

LATANOPROST

Commercializzato da:

LABORATOIRE RIVA INC.

Codice ATC:

S01EE01

INN (Nome Internazionale):

LATANOPROST

Dosaggio:

50MCG

Forma farmaceutica:

SOLUTION

Composizione:

LATANOPROST 50MCG

Via di somministrazione:

OPHTHALMIC

Confezione:

2.5ML

Tipo di ricetta:

Prescription

Area terapeutica:

PROSTAGLANDIN ANALOGS

Dettagli prodotto:

Active ingredient group (AIG) number: 0132916002; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2012-01-27

Scheda tecnica

_RIVA-LATANOPROST (latanoprost) _
_Page 1 de 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RIVA-LATANOPROST
Latanoprost ophthalmic solution
Solution, 50 mcg/mL, Ophthalmic
Prostaglandin F
2α
analogue
Date of Initial Authorization:
JAN
27, 2012
Date of Revision:
OCT
25, 2023
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Submission Control Number: 279978
_RIVA-LATANOPROST (latanoprost) _
_Page 2 de 26 _
RECENT MAJOR LABEL CHANGES
None at the time of most recent authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
..............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
......................................................... 4
4.4
Administration
..........................................................................................................
5
4.5
Missed Dose
.......................................